Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Lower-Risk Myelodysplastic Syndromes
NCT07894861Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 3 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07894861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894861.